Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details)

v3.19.2
Sponsored Research and Clinical Trial Agreements - Summary of Mustang expense related to its sponsored research agreements (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Total licenses acquired expense $ 200 $ 1 $ 650 $ 98
BIDMC - CRISPR [Member]        
Total licenses acquired expense   0 69  
Mustang Therapeutics, Inc [Member]        
Total licenses acquired expense 200   650 75
Research and clinical trial agreements [Member] | Mustang Therapeutics, Inc [Member]        
Total licenses acquired expense 1,670 1,290 3,265 2,680
Research and clinical trial agreements [Member] | Mustang Therapeutics, Inc [Member] | COH CAR T [Member]        
Total licenses acquired expense 500 500 1,000 1,000
Research and clinical trial agreements [Member] | Mustang Therapeutics, Inc [Member] | COH - CD123 (MB-102) [Member]        
Total licenses acquired expense 456 114 759 264
Research and clinical trial agreements [Member] | Mustang Therapeutics, Inc [Member] | COH - IL13Ra2 (MB-101) [Member]        
Total licenses acquired expense 225 143 567 503
Research and clinical trial agreements [Member] | Mustang Therapeutics, Inc [Member] | City Of Hope Manufacturing [Member]        
Total licenses acquired expense 115 115 229 229
Research and clinical trial agreements [Member] | Mustang Therapeutics, Inc [Member] | Fred Hutch-CD20 (MB-106) [Member]        
Total licenses acquired expense $ 374 $ 418 $ 641 $ 684